Deals
Baring Asia Weighs Sale of Japanese Firm Bushu Pharmaceuticals, Sources Say
- Drug contract maker could be valued at more than $750 million
- BPEA set to launch formal sale process as early as next month
This article is for subscribers only.
Baring Private Equity Asia, the buyout fund merging with Swedish investment firm EQT AB, is considering a sale of Japanese drug contract manufacturer Bushu Pharmaceuticals Ltd., people familiar with the matter said.
Hong Kong-based BPEA is working with a financial adviser as it prepares to launch a formal sale process as early as next month, the people said, asking not to be identified because the matter is private. A transaction may value Bushu at upwards of 100 billion yen ($752 million), the people said.